Reichlin S, Frei R, Reusser P
Medizinische Universitätsklinik A, Departement Innere Medizin, Kantonsspital Basel.
Schweiz Med Wochenschr. 1998 Feb 14;128(7):264-7.
A 32-year-old immigrant from Pakistan was admitted to our hospital with cavernous pulmonary tuberculosis. He gave a history of several 1 to 2-months courses of antimycobacterial treatment administered earlier in Pakistan. We initiated combined therapy including isoniazid, rifampin, pyrazinamide, and ethambutol. Subsequently, results of susceptibility testing from M. tuberculosis-complex strains isolated before the onset of treatment documented the presence of resistance against both isoniazid and rifampin which may have been primary or acquired drug resistances. During the course of treatment, two additional resistances to pyrazinamide and ethambutol developed which were probably due to the initial therapy with only two active antimycobacterial agents. The emergence of multidrug-resistant strains of M. tuberculosis complex is a world-wide problem. Our case indicates that multiresistance must be considered in every patient presenting with tuberculosis. If there is a strong suspicion of multidrug-resistant tuberculosis, initial treatment with a combination of 5-6 antimycobacterial agents seems advisable until the results of susceptibility testing become available.
一名32岁的巴基斯坦移民因空洞型肺结核入住我院。他有在巴基斯坦早些时候接受过几次为期1至2个月抗分枝杆菌治疗的病史。我们开始了包括异烟肼、利福平、吡嗪酰胺和乙胺丁醇在内的联合治疗。随后,在治疗开始前分离出的结核分枝杆菌复合菌株的药敏试验结果显示对异烟肼和利福平均耐药,这可能是原发性或获得性耐药。在治疗过程中,又出现了对吡嗪酰胺和乙胺丁醇的耐药,这可能是由于最初仅使用两种有效的抗分枝杆菌药物治疗所致。结核分枝杆菌复合菌多重耐药菌株的出现是一个全球性问题。我们的病例表明,每例肺结核患者都必须考虑多重耐药情况。如果高度怀疑是耐多药结核病,在药敏试验结果出来之前,初始使用5 - 6种抗分枝杆菌药物联合治疗似乎是可取的。